Editas Medicine Inc’s recent filing unveils that its EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda unloaded Company’s shares for reported $1843.0 on Sep 03 ’25. In the deal valued at $2.60 per share,710 shares were sold. As a result of this transaction, Burkly Linda now holds 69,490 shares worth roughly $0.2 million.
Then, Parison Amy sold 458 shares, generating $1,189 in total proceeds. Upon selling the shares at $2.60, the SVP, Chief Financial Officer now owns 16,369 shares.
Before that, O’Neill Gilmore Neil sold 5,592 shares. Editas Medicine Inc shares valued at $14,517 were divested by the CEO at a price of $2.60 per share. As a result of the transaction, O’Neill Gilmore Neil now holds 274,690 shares, worth roughly $0.78 million.
H.C. Wainwright initiated its Editas Medicine Inc [EDIT] rating to a Buy in a research note published on April 28, 2025; the price target was $3. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid December from “a Neutral” to “an Underweight”. Truist also remained covering EDIT and has decreased its forecast on December 13, 2024 with a “Hold” recommendation from previously “Buy” rating. Stifel revised its rating on December 13, 2024. It rated EDIT as “a Hold” which previously was an “a Buy”.
Price Performance Review of EDIT
On Tuesday, Editas Medicine Inc [NASDAQ:EDIT] saw its stock jump 5.99% to $2.83. Over the last five days, the stock has gained 2.54%. Editas Medicine Inc shares have fallen nearly -24.53% since the year began. Nevertheless, the stocks have risen 122.83% over the past one year.
How much short interest is there in Editas Medicine Inc?
A steep rise in short interest was recorded in Editas Medicine Inc stocks on 2025-08-29, dropping by 36831.0 shares to a total of 7.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 7.85 million shares. There was a decline of -0.47%, which implies that there is a negative sentiment for the stock.
